Elicio Therapeutics (ELTX) Accounts Payables (2020 - 2026)

Elicio Therapeutics has reported Accounts Payables for 7 years, with the latest figure at $272000.0 in Q1 2026.

• For the quarter ending Q1 2026, Accounts Payables fell 93.26% year-over-year to $272000.0; the trailing twelve-month figure through Mar 2026 stood at $272000.0 (down 93.26% YoY), and the FY2025 full-year result was $672000.0, down 35.26% from the prior year.
• Accounts Payables for Q1 2026 stood at $272000.0, down from $672000.0 in the prior quarter.
• The five-year high for Accounts Payables was $4.4 million in Q3 2023, with the low at $272000.0 in Q1 2026.
• Historically, Accounts Payables has averaged $2.3 million across 5 years, with a median of $2.2 million in 2022.
• Annual changes were most pronounced in 2025 — Accounts Payables jumped 266.35% — and 2026, when it slumped 93.26%.
• Elicio Therapeutics' Accounts Payables stood at $2.8 million in 2022, then jumped by 55.76% to $4.4 million in 2023, then plunged by 76.24% to $1.0 million in 2024, then tumbled by 35.26% to $672000.0 in 2025, then tumbled by 59.52% to $272000.0 in 2026.
• The last three Accounts Payables figures came in at $272000.0 (Q1 2026), $672000.0 (Q4 2025), and $321000.0 (Q3 2025), per Business Quant data.